Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9636354 | 0.94 | MEN1 (0.46) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9637327 | 0.93 | LMNA (0.48) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9636185 | 0.92 | LMNA (0.47) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9636320 | 0.92 | LMNA (0.47) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9636348 | 0.87 | HTT (0.53) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL9636356 | 0.80 | PKM (0.45) | LMNAALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL9637607 | 0.79 | PKM (0.44) | LMNAALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL9636106 | 0.79 | PKM (0.44) | LMNAALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL11668711 | 0.77 | LMNA (0.58) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4437902 | 0.76 | KMT2A (0.49) | LMNAMEN1KMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0303232-B1 | USE OF BENZYLPYRIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DEMENTIA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-07-29 | — | — | EP | claimed |
| EP-0303232-A2 | Use of benzylpyridine derivatives in the manufacture of a medicament for the treatment of dementia | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-02-15 | — | — | EP | claimed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | RESILIO COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| CN-102333777-B | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2014-06-25 | — | — | CN | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| CN-101815713-B | Polycyclic compounds | EISAI R&D MAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| WO-2010098495-A1 | IMIDAZOLYLPYRAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2148673-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | Eisai R&D Management Co., Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-0303232-B1 | USE OF BENZYLPYRIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DEMENTIA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-4851414-A | AMIDO NITRO BENZYLPYRIDINES | KYOWA HAKKO KAGYO CO., LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0303232-A2 | Use of benzylpyridine derivatives in the manufacture of a medicament for the treatment of dementia | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | LMNA 2715/4885MEN1 1880/4885KMT2A 183/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | LMNA 3966/4885MEN1 4095/4885KMT2A 4685/4885 |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | BDNF, BACE1, GAP43 | LMNA 1688/4885MEN1 2307/4885KMT2A 3851/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | LMNA 899/4885MEN1 531/4885KMT2A 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.